JP2014533743A5 - - Google Patents

Download PDF

Info

Publication number
JP2014533743A5
JP2014533743A5 JP2014543984A JP2014543984A JP2014533743A5 JP 2014533743 A5 JP2014533743 A5 JP 2014533743A5 JP 2014543984 A JP2014543984 A JP 2014543984A JP 2014543984 A JP2014543984 A JP 2014543984A JP 2014533743 A5 JP2014533743 A5 JP 2014533743A5
Authority
JP
Japan
Prior art keywords
therapy
cancer
immunostimulant
tumor
cell death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014543984A
Other languages
English (en)
Japanese (ja)
Other versions
JP6085611B2 (ja
JP2014533743A (ja
Filing date
Publication date
Priority claimed from GBGB1120779.2A external-priority patent/GB201120779D0/en
Application filed filed Critical
Publication of JP2014533743A publication Critical patent/JP2014533743A/ja
Publication of JP2014533743A5 publication Critical patent/JP2014533743A5/ja
Application granted granted Critical
Publication of JP6085611B2 publication Critical patent/JP6085611B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014543984A 2011-12-02 2012-12-03 癌免疫療法 Active JP6085611B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1120779.2 2011-12-02
GBGB1120779.2A GB201120779D0 (en) 2011-12-02 2011-12-02 Cancer therapy
PCT/GB2012/052992 WO2013079980A1 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer

Publications (3)

Publication Number Publication Date
JP2014533743A JP2014533743A (ja) 2014-12-15
JP2014533743A5 true JP2014533743A5 (cg-RX-API-DMAC7.html) 2016-01-28
JP6085611B2 JP6085611B2 (ja) 2017-02-22

Family

ID=45509083

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014543984A Active JP6085611B2 (ja) 2011-12-02 2012-12-03 癌免疫療法

Country Status (15)

Country Link
US (4) US20140356397A1 (cg-RX-API-DMAC7.html)
EP (1) EP2785361B1 (cg-RX-API-DMAC7.html)
JP (1) JP6085611B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140097419A (cg-RX-API-DMAC7.html)
CN (1) CN104023733A (cg-RX-API-DMAC7.html)
AU (1) AU2012343536B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014012880A2 (cg-RX-API-DMAC7.html)
CA (1) CA2857429A1 (cg-RX-API-DMAC7.html)
GB (1) GB201120779D0 (cg-RX-API-DMAC7.html)
IL (1) IL232890A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014MN00955A (cg-RX-API-DMAC7.html)
MX (1) MX2014006511A (cg-RX-API-DMAC7.html)
RU (1) RU2014121335A (cg-RX-API-DMAC7.html)
SG (1) SG11201402396XA (cg-RX-API-DMAC7.html)
WO (1) WO2013079980A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11963716B2 (en) 2010-07-19 2024-04-23 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201308325D0 (en) * 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
FI3077041T3 (fi) 2013-12-05 2024-10-16 Rfemb Holdings Llc Syövän immunoterapia radiotaajuisella sähköisellä solukalvon hajotuksella (rf-emb)
GB201322725D0 (en) * 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
US11141216B2 (en) 2015-01-30 2021-10-12 Immunsys, Inc. Radio-frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue
PL3319635T3 (pl) * 2015-06-24 2021-10-25 Immodulon Therapeutics Limited Inhibitor punktu kontrolnego i prątek całokomórkowy do stosowania w terapii nowotworowej
RU2596505C1 (ru) * 2015-07-02 2016-09-10 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) Способ лечения онкологических больных цитотоксическими лимфоцитами
US10478194B2 (en) 2015-09-23 2019-11-19 Covidien Lp Occlusive devices
CA3011460A1 (en) 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunologic treatment of cancer
RU2018136347A (ru) * 2016-04-14 2020-05-14 Фелдрайх Каро Руиз Аб Аппарат для радиационной терапии, включающий модуль ионизации и источник ультрафиолетового света
CA3058380A1 (en) 2017-03-28 2018-10-04 Emblation Limited Stenosis treatment
US11173325B2 (en) 2017-07-21 2021-11-16 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agent
RU2664597C1 (ru) * 2017-12-12 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения больных первично операбельным и местно-распространенным неоперабельным раком молочной железы
MA54399A (fr) 2018-12-03 2021-10-13 Fusion Pharmaceuticals Inc Radioimmunoconjugués et polythérapie à base d'inhibiteur de point de contrôle
US20220098578A1 (en) * 2019-01-31 2022-03-31 Bar Ilan University Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
US20230045616A1 (en) * 2019-12-27 2023-02-09 Nonprofit Organization North East Japan Study Group Cancer treatment method and medicine
EP4376945A1 (en) * 2021-07-27 2024-06-05 Immodulon Therapeutics Limited A mycobacterium for use in cancer therapy
CN114367060A (zh) * 2022-01-13 2022-04-19 深圳大学 激光交变电场联合治疗仪

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5207223A (en) 1990-10-19 1993-05-04 Accuray, Inc. Apparatus for and method of performing stereotaxic surgery
EP0556248B1 (en) * 1990-11-08 1997-06-25 University College London Mycobacterium as adjuvant for antigens
US5458125A (en) 1994-01-28 1995-10-17 Board Of Directors Of The Leland Standford Jr. University Treatment planning method and apparatus for radiosurgery and radiation therapy
WO2000064476A2 (en) 1999-04-23 2000-11-02 Qlt Inc. Immuno-adjuvant pdt treatment of metastatic tumors
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
AU2002353366A1 (en) * 2001-12-10 2003-06-23 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
WO2004006837A2 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
US20090297540A1 (en) 2005-10-21 2009-12-03 Andrew Mellor Induction of Indoleamine 2,3-Dioxygenase in Dendritic Cells by TLR Ligands and Uses thereof
US20080318252A1 (en) 2007-04-23 2008-12-25 Scott Kachlany Rapid assay to test anti-cancer drugs under physiological conditions
GB0526033D0 (en) * 2005-12-21 2006-02-01 Bioeos Ltd Method
US8557257B2 (en) * 2006-03-24 2013-10-15 Oncovac Inc. Mycobacterial immunotherapy for cancer treatment
WO2008110491A2 (en) 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
PT2172211E (pt) * 2008-10-01 2015-03-09 Immatics Biotechnologies Gmbh Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer
US8367075B2 (en) 2010-07-02 2013-02-05 Indian Institute Of Science Synergistic combination and method thereof
US9114158B2 (en) * 2011-03-09 2015-08-25 The Johns Hopkins University Compounds and methods of use in ablative radiotherapy
WO2012177624A2 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
EP2620159A1 (en) 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
WO2013114367A2 (en) 2012-02-01 2013-08-08 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
US8617520B2 (en) 2012-02-15 2013-12-31 Immodulon Therapeutics Limited Cancer therapy
GB201308325D0 (en) 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
EP3092004A4 (en) 2014-01-06 2017-02-22 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
PL3319635T3 (pl) 2015-06-24 2021-10-25 Immodulon Therapeutics Limited Inhibitor punktu kontrolnego i prątek całokomórkowy do stosowania w terapii nowotworowej
CN112672758A (zh) 2018-06-25 2021-04-16 英摩杜伦治疗学公司 癌症治疗

Similar Documents

Publication Publication Date Title
JP2014533743A5 (cg-RX-API-DMAC7.html)
Ta et al. Thermosensitive liposomes for localized delivery and triggered release of chemotherapy
Vogl et al. Radiofrequency, microwave and laser ablation of pulmonary neoplasms: clinical studies and technical considerations
JP6085611B2 (ja) 癌免疫療法
Lencioni et al. Image-guided ablation of malignant liver tumors: recommendations for clinical validation of novel thermal and non-thermal technologies-a western perspective
Sivaraman et al. Focal therapy for prostate cancer: an “Àla carte” approach
Li et al. Locally ablative therapies for primary and metastatic liver cancer
Friedman et al. The use of hybrid radiofrequency device for the treatment of rhytides and lax skin
Tian et al. Cryoablation and immune synergistic effect for lung cancer: A review
Hulshof et al. Preoperative chemoradiation combined with regional hyperthermia for patients with resectable esophageal cancer
Spiliopoulos et al. Irreversible electroporation for the management of pancreatic cancer: Current data and future directions
Liu et al. Rhythmic mild photothermal therapy enhancing anti-PD-L1 response for oral squamous cell carcinoma immunotherapy
Hirohashi et al. Photothermal ablation of human lung cancer by low-power near-infrared laser and topical injection of indocyanine green
WO2005084387A3 (en) Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer
Rusthoven et al. Stereotactic body radiation therapy (SBRT) for liver metastases: a clinical review
Barajas et al. Radiofrequency ablation: a review of current knowledge, therapeutic perspectives, complications, and contraindications
Moghadam et al. A brief review of Hyperthermia as a neoadjuvant therapy method related to cancer treatment
CN103006316B (zh) 一种冷热刀
Thosani et al. LONG-TERM OUTCOMES OF ENDOSCOPIC ULTRASOUND-GUIDED RADIOFREQUENCY ABLATION (EUS-RFA) FOR ADVANCED PANCREATIC AND PERIAMPULLARY ADENOCARCINOMA
Jing et al. Use of hapten combined cytotoxic drugs for enhancing therapeutic effect in advanced stages of pancreatic cancer
Hof et al. Stereotactic irradiation of lung tumors
Stone et al. Emerging local ablation techniques
Idrees et al. A review on potential benefits of hyperthermia in the treatment of cancer
CN103006315B (zh) 一种冷热刀
Ahmed et al. Principles of radiofrequency ablation